Whalesbook
Toh bhaiyo, baat yeh hai ki ICICI Securities ka kehna hai ki upcoming Q4 FY26 mein Indian pharma companies ka revenue toh thik-thak badhega, lagbhag 7.2% tak, par asal mein unka net profit lagbhag 13.3% tak gir sakta hai. Yeh jo gap hai na revenue badhne aur profit ghatne ka, yeh dikhata hai ki market mein pressure bahut hai, specially bade patent expires ki wajah se.
Revlimid Ka Chakkar Aur Profit Pe Attack
Sabse bada reason hai gRevlimid drug ka patent expiry, jo January 2026 mein aane wala hai. ICICI Securities ka forecast hai ki is wajah se operating profit (Ebitda) 2.4% aur net profit (PAT) 13.3% tak kam ho sakta hai. Jo companies is Revlimid drug par bahut zyada depend karti hain, jaise Dr. Reddy's Laboratories, Zydus Lifesciences, aur Cipla, unka performance sach mein gir sakta hai. Dr. Reddy's ko toh oncology segment se seedha revenue loss hone ka dar hai. Investors bhi thode confused hain, isi liye stock prices mein bhi upar-niche dekhne ko mil raha hai, kyunki sab log ab future mein aane wale revenue loss aur usse recover karne ke liye naye drugs banane ke kharche ka hisab laga rahe hain.
Kaha Milegi Raahat? Desi Market Aur Nayi Strategy
Lekin bhai, sab companies ki situation same nahi hai. ICICI Securities ne kuch companies ko select kiya hai jo acha perform kar sakti hain. Lupin se acche results ki umeed hai kyunki unke paas alag alag products hain aur woh key markets mein strong hain. Jo companies India ke desi market par zyada focus karti hain, jaise Torrent Pharmaceuticals, woh acquisitions ke through aur grow karengi. Torrent ne JB Chemicals & Pharmaceuticals ko kharida hai, jisse unka market share aur product range badhega. Alkem Laboratories, jo ek India-focused company hai, uska bhi quarter strong rehne ka guess hai, unke badhte treatment areas aur strong sales team ki wajah se. Gland Pharma se bhi decent growth ki ummeed hai, specially naye product launches se, although injectables mein competition badh raha hai. Lekin, jo companies innovation pe focus karti hain aur dusron ke liye drugs banati hain (CDMOs), jaise Divi's Laboratories, Piramal Pharma, aur Cohance, unka outlook thoda kamzor lag raha hai. Unka project revenue development phases aur R&D budget changes ki wajah se unpredictable ho sakta hai.
Risks Aur Valuations Ka Dhyan Rakho
ICICI Securities ne Sun Pharmaceutical Industries, Aurobindo Pharma, Alkem Laboratories, Gland Pharma, OneSource, Piramal Pharma, aur Akums Drugs & Pharmaceuticals jaise stocks ko top picks bataya hai, par kuch risks ko bhi dhyan mein rakhna zaroori hai. Sector ka predicted 7.2% revenue growth bhi kam lag raha hai jab profits itne zyada girne wale hain, matlab margins aur tight ho sakte hain. Dr. Reddy's aur Cipla jaise companies ke liye Revlimid se hone wale revenue loss ko cover karna tabhi hoga jab woh jaldi se profitable naye drugs launch kar payenge, jismein regulatory challenges aur tough competition hai. Sun Pharma, jiske paas bahut saare specialized drugs development mein hain, aur Aurobindo Pharma, jo biosimilars mein expand kar raha hai, woh shayad steady growth dikha payein. Bahut saari companies ke stock valuations abhi bhi high hain, bade companies 20x se 30x P/E ratios par trade kar rahe hain, matlab agar growth targets miss huye toh girne ka risk hai. Upar se, Indian pharma sector par fluctuating exchange rates aur raw materials ke badhte kharche ka bhi pressure hai, jo profits ko aur kam kar sakta hai. Technicals dekhein toh RSI mostly neutral (45-60) hai, matlab abhi koi zabardast momentum nahi hai jo earnings disappointments ko absorb kar sake. Iss sab ke beech, companies jo specialty products aur biosimilars par focus kar rahi hain, woh future mein acha kar sakti hain. Abhi dekhte hain kaun apni strategy mein successful hota hai!